1. Home
  2. PHAR vs PAHC Comparison

PHAR vs PAHC Comparison

Compare PHAR & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$16.35

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Phibro Animal Health Corporation

PAHC

Phibro Animal Health Corporation

N/A

Current Price

$40.85

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PHAR
PAHC
Founded
1988
1946
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.6B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PHAR
PAHC
Price
$16.35
$40.85
Analyst Decision
Strong Buy
Hold
Analyst Count
3
4
Target Price
$30.00
$31.25
AVG Volume (30 Days)
23.9K
273.3K
Earning Date
11-06-2025
02-04-2026
Dividend Yield
N/A
1.18%
EPS Growth
N/A
288.74
EPS
0.00
1.67
Revenue
$362,274,000.00
$1,399,676,000.00
Revenue This Year
$24.80
$15.34
Revenue Next Year
$6.84
$3.28
P/E Ratio
$2,952.77
$24.30
Revenue Growth
26.78
33.72
52 Week Low
$7.50
$16.16
52 Week High
$18.12
$46.42

Technical Indicators

Market Signals
Indicator
PHAR
PAHC
Relative Strength Index (RSI) 51.04 48.16
Support Level $16.23 $39.78
Resistance Level $18.12 $41.62
Average True Range (ATR) 0.83 1.76
MACD -0.13 -0.07
Stochastic Oscillator 36.86 42.53

Price Performance

Historical Comparison
PHAR
PAHC

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Share on Social Networks: